Filtered By:
Vaccination: Cancer Vaccines
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 7677 results found since Jan 2013.
Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals
CONCLUSIONS: When administered before 14 years of age, qHPV vaccination reduced the probability of AGW about fivefold. The effect decreased sharply with vaccination age, and was not significant among women vaccinated after age 20 years. QHPV administered after the first AGW episode did not protect against a second AGW episode. Herd effects were indicated in unvaccinated males, as we observed a gradual decrease in AGW rates from the 1993 male birth cohort and onwards.PMID:37516572 | DOI:10.1016/j.vaccine.2023.07.031
Source: Vaccine - July 29, 2023 Category: Allergy & Immunology Authors: St åle Nygård Mari Nyg ård Madleen Orumaa Bo T Hansen Source Type: research
Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications
Cancers (Basel). 2023 Jul 20;15(14):3692. doi: 10.3390/cancers15143692.ABSTRACTThere is a significant body of research examining the role of human papillomavirus (HPV) in the pathogenesis of cervical cancer, with a particular emphasis on the oncogenic proteins E5, E6, and E7. What is less well explored, however, is the relationship between cervical cancer and herpes simplex virus (HSV). To date, studies examining the role of HSV in cervical cancer pathogenesis have yielded mixed results. While several experiments have determined that HPV/HSV-2 coinfection results in a higher risk of developing cervical cancer, others have ...
Source: Herpes - July 29, 2023 Category: Infectious Diseases Authors: Daniel G Sausen Oren Shechter Elisa S Gallo Harel Dahari Ronen Borenstein Source Type: research
Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals
CONCLUSIONS: When administered before 14 years of age, qHPV vaccination reduced the probability of AGW about fivefold. The effect decreased sharply with vaccination age, and was not significant among women vaccinated after age 20 years. QHPV administered after the first AGW episode did not protect against a second AGW episode. Herd effects were indicated in unvaccinated males, as we observed a gradual decrease in AGW rates from the 1993 male birth cohort and onwards.PMID:37516572 | DOI:10.1016/j.vaccine.2023.07.031
Source: Cancer Control - July 29, 2023 Category: Cancer & Oncology Authors: St åle Nygård Mari Nyg ård Madleen Orumaa Bo T Hansen Source Type: research
Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development
Vaccines (Basel). 2023 Jul 8;11(7):1218. doi: 10.3390/vaccines11071218.ABSTRACTVaccination is one of the most effective strategies to control epidemics. With the deepening of people's awareness of vaccination, there is a high demand for vaccination. Hence, a flexible, rapid, and cost-effective vaccine platform is urgently needed. The baculovirus expression vector system (BEVS) has emerged as a promising technology for vaccine production due to its high safety, rapid production, flexible product design, and scalability. In this review, we introduced the development history of BEVS and the procedures for preparing recombinan...
Source: Cancer Control - July 29, 2023 Category: Cancer & Oncology Authors: Qiaonan Hong Jian Liu Yuquan Wei Xiawei Wei Source Type: research
Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study
Vaccines (Basel). 2023 Jul 3;11(7):1193. doi: 10.3390/vaccines11071193.ABSTRACTCancer patients on chemotherapy have a lower immune response to SARS-CoV-2 vaccines. Therefore, through a prospective cohort study of patients with solid tumors receiving chemotherapy, we aimed to determine the immunogenicity of an mRNA vaccine booster (BNT162b2) among patients previously immunized with an inactivated (CoronaVac) or homologous (BNT162b2) SARS-CoV-2 vaccine. The primary outcome was the proportion of patients with anti-SARS-CoV-2 neutralizing antibody (NAb) seropositivity at 8-12 weeks post-booster. The secondary end points includ...
Source: Cancer Control - July 29, 2023 Category: Cancer & Oncology Authors: Sebasti án Mondaca Benjam ín Walbaum Nicole Le Corre Marcela Ferr és Alejandro Vald és Constanza Mart ínez-Valdebenito Cinthya Ruiz-Tagle Patricia Macanas-Pirard Patricio Ross Betzab é Cisternas Patricia P érez Olivia Cabrera Valentina Cerda Ivana Source Type: research
Understanding Concerns about COVID-19 and Vaccination: Perspectives from Kidney Transplant Recipients
Vaccines (Basel). 2023 Jun 22;11(7):1134. doi: 10.3390/vaccines11071134.ABSTRACTThe COVID-19 pandemic poses a significant risk for immunosuppressed groups such as transplant patients. The purpose of this study was to improve our understanding of the impact of the COVID-19 pandemic on kidney transplant recipients, including their views on COVID-19 vaccination. Semi-structured interviews were conducted from December 2021 to August 2022 with 38 kidney transplant recipients who had an appointment with their transplant care team within the previous 6 months. We used qualitative thematic analysis to characterize the perspectives...
Source: Cancer Control - July 29, 2023 Category: Cancer & Oncology Authors: Sarah R MacEwan Alice A Gaughan Graham N Dixon Ramona G Olvera Willi L Tarver Saurabh Rahurkar Laura J Rush Austin D Schenk Jack Stevens Ann Scheck McAlearney Source Type: research
The Clinical Utility of Circulating HPV DNA Biomarker in Oropharyngeal, Cervical, Anal, and Skin HPV-Related Cancers: A Review
Pathogens. 2023 Jul 5;12(7):908. doi: 10.3390/pathogens12070908.ABSTRACTHuman papillomavirus (HPV) is recognized as being related to a wide variety of known cancers: cervical, oropharyngeal, anal, vaginal, penile, and skin. For some of these cancers, rigorous algorithms for screening, therapeutical interventions, and follow-up procedures have been established. Vaccination using the nonvalent anti-HPV vaccine, which prevents infection regarding the most frequently involved high-risk HPV types (16, 18, 31, 33, 45, 52, and 58) and low-risk HPV types (6 and 11), has also extensively prevented, controlled, and even eradicated H...
Source: Cancer Control - July 29, 2023 Category: Cancer & Oncology Authors: Ioana Maria Andrioaie Ionut Luchian Costin D ămian Giorgio Nichitean Elena Porumb Andrese Theodor Florin Pantilimonescu Bogdan Trandab ăț Liviu Jany Prisacariu Dana Gabriela Budal ă Daniela Cristina Dimitriu Luminita Smaranda Iancu Ramona Gabriela Urs Source Type: research
Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications
Cancers (Basel). 2023 Jul 20;15(14):3692. doi: 10.3390/cancers15143692.ABSTRACTThere is a significant body of research examining the role of human papillomavirus (HPV) in the pathogenesis of cervical cancer, with a particular emphasis on the oncogenic proteins E5, E6, and E7. What is less well explored, however, is the relationship between cervical cancer and herpes simplex virus (HSV). To date, studies examining the role of HSV in cervical cancer pathogenesis have yielded mixed results. While several experiments have determined that HPV/HSV-2 coinfection results in a higher risk of developing cervical cancer, others have ...
Source: Herpes - July 29, 2023 Category: Infectious Diseases Authors: Daniel G Sausen Oren Shechter Elisa S Gallo Harel Dahari Ronen Borenstein Source Type: research
Impact of an autophagy-inducing peptide on immunogenicity and protection efficacy of an adenovirus-vectored SARS-CoV-2 vaccine
Mol Ther Methods Clin Dev. 2023 Jun 27;30:194-207. doi: 10.1016/j.omtm.2023.06.009. eCollection 2023 Sep 14.ABSTRACTBecause of continual generation of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is critical to design the next generation of vaccines to combat the threat posed by SARS-CoV-2 variants. We developed human adenovirus (HAd) vector-based vaccines (HAd-Spike/C5 and HAd-Spike) that express the whole Spike (S) protein of SARS-CoV-2 with or without autophagy-inducing peptide C5 (AIP-C5), respectively. Mice or golden Syrian hamsters immunized intranasally (i.n.) with HAd-Spike/C5 in...
Source: Clinical Lung Cancer - July 28, 2023 Category: Cancer & Oncology Authors: Ekramy E Sayedahmed Marcelo Valdemir Ara újo Taiana Tain á Silva-Pereira Shubhada K Chothe Ahmed Elkashif Marwa Alhashimi Wen-Chien Wang Andrea P Santos Meera Surendran Nair Abhinay Gontu Ruth Nissly Ant ônio Francisco de Souza Filho Mariana Silva Tava Source Type: research
Targeted vaccine development against Bilophila wadsworthia to curb colon diseases: A multiepitope approach based on reverse vaccinology and computational analysis
Int J Biol Macromol. 2023 Jul 26:126002. doi: 10.1016/j.ijbiomac.2023.126002. Online ahead of print.ABSTRACTThe presence of excessive hydrogen sulfide (H2S)-producing bacteria, particularly Bilophila wadsworthia in appendices, is linked to a weaker colonic mucus barrier, inflammatory bowel disease, and colorectal cancer. Thus, targeting this bacterium could reduce sulfide levels and address associated health concerns. Here, we utilized reverse vaccinology and immunoinformatics to design a chimeric vaccine against B. wadsworthia, focusing on membrane-bound and extracellular proteins. Subtractive proteome analysis identified...
Source: International Journal of Biological Macromolecules - July 28, 2023 Category: Biochemistry Authors: Sara Khan Shahkaar Aziz Muhammad Waqas Muhammad Azam Kakar Sohail Ahmad Source Type: research
Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination
This study indicates that CD33/Siglec-3 may serve as a predictor of HIV-1 control and as potential therapeutic tool to improve future cure strategies.FUNDING: Spanish Science and Innovation Ministry (SAF2017-89726-R and PID2020-119710RB-I00), NIH (P01-AI131568), European Commission (GA101057548) and a Grifols research agreement.PMID:37506557 | DOI:10.1016/j.ebiom.2023.104732
Source: Cancer Control - July 28, 2023 Category: Cancer & Oncology Authors: Clara Duran-Castells Anna Prats Bruna Oriol-Tordera Anuska Llano Cristina Galvez Javier Martinez-Picado Ester Ballana Edurne Garcia-Vidal Bonaventura Clotet Jose A Mu ñoz-Moreno Thomas Hanke Jos é Moltó Beatriz Mothe Christian Brander Marta Ruiz-Riol Source Type: research
Impact of an autophagy-inducing peptide on immunogenicity and protection efficacy of an adenovirus-vectored SARS-CoV-2 vaccine
Mol Ther Methods Clin Dev. 2023 Jun 27;30:194-207. doi: 10.1016/j.omtm.2023.06.009. eCollection 2023 Sep 14.ABSTRACTBecause of continual generation of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is critical to design the next generation of vaccines to combat the threat posed by SARS-CoV-2 variants. We developed human adenovirus (HAd) vector-based vaccines (HAd-Spike/C5 and HAd-Spike) that express the whole Spike (S) protein of SARS-CoV-2 with or without autophagy-inducing peptide C5 (AIP-C5), respectively. Mice or golden Syrian hamsters immunized intranasally (i.n.) with HAd-Spike/C5 in...
Source: Clinical Lung Cancer - July 28, 2023 Category: Cancer & Oncology Authors: Ekramy E Sayedahmed Marcelo Valdemir Ara újo Taiana Tain á Silva-Pereira Shubhada K Chothe Ahmed Elkashif Marwa Alhashimi Wen-Chien Wang Andrea P Santos Meera Surendran Nair Abhinay Gontu Ruth Nissly Ant ônio Francisco de Souza Filho Mariana Silva Tava Source Type: research
Health Literacy and COVID-19 Vaccination among Cancer Patients in Northeastern Thailand: A Cross-Sectional Study
CONCLUSIONS: The strongest predictor of receiving COVID-19 vaccines was health literacy, which enhances healthcare provider awareness of communicable disease prevention and control for patients with cancer as well as counselling and educating to improve their health literacy. It could influent a higher rate of vaccine uptake among patients with cancer.PMID:37505769 | DOI:10.31557/APJCP.2023.24.7.2375
Source: Cancer Control - July 28, 2023 Category: Cancer & Oncology Authors: Phichet Dapha Surachai Phimha Nakarin Prasit Nopparat Senahad Source Type: research
Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment
In this study, we demonstrate, for the first time, that treating established syngeneic murine colon and breast carcinoma tumors with a CSF1R-blocking antibody also promotes the expansion of neoepitope-specific T cells. To assess the role of tumor-derived CSF1 in these model systems, we generated and characterized CSF1 CRISPR-Cas9 knockouts. Eliminating tumor-derived CSF1 results in decreased tumor growth and enhanced immunity against tumor-associated neoepitopes, potentially promoting an immune permissive tumor microenvironment in tumor-bearing mice. The combination of neoepitope vaccine with anti-PDL1 in the MC38 CSF1-/- ...
Source: Cancer Control - July 28, 2023 Category: Cancer & Oncology Authors: Maria Del Mar Maldonado Jeffrey Schlom Duane H Hamilton Source Type: research
